A phase 1B/2 study to evaluate safety and anti-tumor act

Project: Research project

Project Details

Description

A phase 1B/2 study to evaluate safety and anti-tumor activity of avelumab in combination with the poly (adenosine diphosphate [adp]-ribose) polymerase (parp) inhibitor talazoparib in patients with locally advanced or metastatic solid tumors
StatusActive
Effective start/end date11/1/1711/30/21

Funding

  • PFIZER, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.